Context Therapeutics Inc. today announced that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, at the McCormick Place Convention Center in Chicago, IL.